Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A.

Cancer Cell. 2010 Dec 14;18(6):553-67. doi: 10.1016/j.ccr.2010.11.015. Epub 2010 Dec 9.

2.

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.

Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A.

Nature. 2010 Dec 9;468(7325):839-43. doi: 10.1038/nature09586.

3.

Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.

Candelaria M, Herrera A, Labardini J, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Pérez-Cárdenas E, de la Cruz-Hernández E, Arias-Bofill D, Vidal S, Cervera E, Dueñas-Gonzalez A.

Ann Hematol. 2011 Apr;90(4):379-87. doi: 10.1007/s00277-010-1090-2. Epub 2010 Oct 5.

PMID:
20922525
4.

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.

Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC, Przychodzen B, Mian SA, Nasser EE, Shooter C, Westwood NB, Strupp C, Gattermann N, Maciejewski JP, Germing U, Mufti GJ.

Blood. 2010 Nov 11;116(19):3923-32. doi: 10.1182/blood-2010-03-274704. Epub 2010 Aug 6.

5.

Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B, Dicker F, Schnittger S, Dugas M, Kern W, Haferlach C, Haferlach T.

J Clin Oncol. 2010 Aug 20;28(24):3858-65. doi: 10.1200/JCO.2009.27.1361. Epub 2010 Jul 19.

PMID:
20644105
6.

TIF1gamma controls erythroid cell fate by regulating transcription elongation.

Bai X, Kim J, Yang Z, Jurynec MJ, Akie TE, Lee J, LeBlanc J, Sessa A, Jiang H, DiBiase A, Zhou Y, Grunwald DJ, Lin S, Cantor AB, Orkin SH, Zon LI.

Cell. 2010 Jul 9;142(1):133-43. doi: 10.1016/j.cell.2010.05.028.

7.

Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells.

Paggetti J, Largeot A, Aucagne R, Jacquel A, Lagrange B, Yang XJ, Solary E, Bastie JN, Delva L.

Oncogene. 2010 Sep 9;29(36):5019-31. doi: 10.1038/onc.2010.254. Epub 2010 Jun 28.

PMID:
20581860
8.

Negative control of Smad activity by ectodermin/Tif1gamma patterns the mammalian embryo.

Morsut L, Yan KP, Enzo E, Aragona M, Soligo SM, Wendling O, Mark M, Khetchoumian K, Bressan G, Chambon P, Dupont S, Losson R, Piccolo S.

Development. 2010 Aug 1;137(15):2571-8. doi: 10.1242/dev.053801. Epub 2010 Jun 23.

9.

A major role of TGF-beta1 in the homing capacities of murine hematopoietic stem cell/progenitors.

Capron C, Lacout C, Lécluse Y, Jalbert V, Chagraoui H, Charrier S, Galy A, Bennaceur-Griscelli A, Cramer-Bordé E, Vainchenker W.

Blood. 2010 Aug 26;116(8):1244-53. doi: 10.1182/blood-2009-05-221093. Epub 2010 May 20.

10.

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.

Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, Solary E, Birnbaum D, Bernard OA, Fontenay M.

Leukemia. 2010 May;24(5):1094-6. doi: 10.1038/leu.2010.52. Epub 2010 Apr 8. No abstract available.

PMID:
20376084
11.

Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1.

Challen GA, Boles NC, Chambers SM, Goodell MA.

Cell Stem Cell. 2010 Mar 5;6(3):265-78. doi: 10.1016/j.stem.2010.02.002.

12.

Histone modification levels are predictive for gene expression.

Karlić R, Chung HR, Lasserre J, Vlahovicek K, Vingron M.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2926-31. doi: 10.1073/pnas.0909344107. Epub 2010 Feb 1.

13.

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.

Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, Quesnel B, Fenaux P, Bastie JN, Beyne-Rauzy O, Stamatoulas A, Dreyfus F, Ifrah N, de Botton S, Vainchenker W, Bernard OA, Birnbaum D, Fontenay M, Solary E; Groupe Francophone des Myélodysplasies.

Haematologica. 2009 Dec;94(12):1676-81. doi: 10.3324/haematol.2009.011205. Epub 2009 Oct 1.

14.

Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas.

Vincent DF, Yan KP, Treilleux I, Gay F, Arfi V, Kaniewski B, Marie JC, Lepinasse F, Martel S, Goddard-Leon S, Iovanna JL, Dubus P, Garcia S, Puisieux A, Rimokh R, Bardeesy N, Scoazec JY, Losson R, Bartholin L.

PLoS Genet. 2009 Jul;5(7):e1000575. doi: 10.1371/journal.pgen.1000575. Epub 2009 Jul 24. Erratum in: PLoS Genet. 2009 Aug;5(8). doi: 10.1371/annotation/7941c465-532f-4b42-b541-72d0810943b9. Kaniewsky, Bastien [corrected to Kaniewski, Bastien].

15.

iNKT cell development is orchestrated by different branches of TGF-beta signaling.

Doisne JM, Bartholin L, Yan KP, Garcia CN, Duarte N, Le Luduec JB, Vincent D, Cyprian F, Horvat B, Martel S, Rimokh R, Losson R, Benlagha K, Marie JC.

J Exp Med. 2009 Jun 8;206(6):1365-78. doi: 10.1084/jem.20090127. Epub 2009 May 18.

16.

Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Gelsi-Boyer V, Trouplin V, Adélaïde J, Bonansea J, Cervera N, Carbuccia N, Lagarde A, Prebet T, Nezri M, Sainty D, Olschwang S, Xerri L, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D.

Br J Haematol. 2009 Jun;145(6):788-800. doi: 10.1111/j.1365-2141.2009.07697.x. Epub 2009 Apr 15.

PMID:
19388938
17.

RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.

Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, Shih LY.

Leukemia. 2009 Aug;23(8):1426-31. doi: 10.1038/leu.2009.48. Epub 2009 Mar 12.

PMID:
19282830
18.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group.

Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.

19.

FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination.

Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ, Soligo S, Morsut L, Inui M, Moro S, Modena N, Argenton F, Newfeld SJ, Piccolo S.

Cell. 2009 Jan 9;136(1):123-35. doi: 10.1016/j.cell.2008.10.051.

20.

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM.

Blood. 2009 Feb 19;113(8):1749-55. doi: 10.1182/blood-2008-04-152157. Epub 2008 Dec 15.

Supplemental Content

Support Center